During the 2026 Zhongguancun Forum Annual Conference, Xinhua News Agency conducted an on site visit to the AccuMedical exhibition booth and invited the Founder and Chief Executive Officer of AccuMedical, Yi Ran Lv, for a feature interview to present to the global audience the “Chinese Precision” in the field of neurointervention.
The visit report was published on Xinhua News App, as well as Xinhua’s Facebook, YouTube, and X accounts.
01 In Depth Dialogue: From “Accu” to AccuMedical’s Original Aspiration
In the interview, CEO Yi Ran Lv deeply articulated the brand philosophy. The English name “AccuMedical”—derived from “Accurate”—is not merely a name, but a reflection of the company’s pursuit of precision in every surgery, every vascular pathway, and every micron level manipulation.
“Neurointerventional procedures demand near exacting precision,” Lv explained, “and our mission is to transform high risk traditional surgeries into safer, more efficient minimally invasive solutions through continuous innovation.”
02 Hard Core Demonstration: Full Stack Neurointervention Solutions
Through an on site demonstration, Yi Ran Lv shared the outstanding performance of AccuMedical’s products:
“For cerebrovascular diseases, which are highly prevalent among Chinese and other Asian populations, AccuMedical is enhancing the safety and effectiveness of procedures through designs that better address clinical pain points.”
03 Data Led Leadership: Outstanding Clinical Performance Metrics
Clinical data serve as the ultimate benchmark of product capability. During the interview, Lv shared the latest scientific findings on the Lattice® Flow Diverter.
“According to the latest literature[1], while maintaining excellent complete occlusion rates, the in stent stenosis (ISS) of the Lattice® Flow Diverter has dropped to 1.8% , a rate far below the 14.5% reported for conventional international devices, reaching a world leading level.”
Having participated in the Zhongguancun Forum for three consecutive years, AccuMedical has grown increasingly resolute in its path. We are not only intensively advancing research and development, tackling multiple core underlying technologies such as stent delivery system architecture and surface material modification, but also committed to promoting the “China Standard” on a global scale.
Guided by its founding principle of “Precise, Treat as Our Own,” AccuMedical will continue to push the boundaries of complex procedure technologies with innovation, further safeguard life.
References:
[1]: Bao, L., He, S., & Zhang, Y. (2026). Abstract DP322: Comparison of Lattice flow diverter and pipeline embolization device in Unruptured Intracranial Aneurysms: A Real-World, Propensity Score-Matching Study. Stroke, 57(Suppl_1). https://doi.org/10.1161/str.57.suppl_1.dp322